Nadja Y. West - 23 Apr 2026 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Reporting relationship: Director
Issuer ticker: JNJ
Reported as of: 23 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Apr 2026, 18:21:49 UTC
Prior SEC filing: 18 Feb 2026
Next SEC filing: 26 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Joleen Morgan, as attorney-in-fact for Nadja Y. West

Key filing fact

Nadja Y. West filed Form 4 for JOHNSON & JOHNSON (JNJ) on 27 Apr 2026.

Key facts

This page summarizes Nadja Y. West's Form 4 filing for JOHNSON & JOHNSON (JNJ).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Apr 2026, 18:21.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001787802 Primary reporting owner

West Nadja

Relationship: Director
Address: ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK
Signature: /s/ Joleen Morgan, as attorney-in-fact for Nadja Y. West
Signature date: 27 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JNJ transaction Derivative

Deferred Share Units

Award

Transaction value
Shares: +975
Change %: +14%
Price: $0.000000^*
Shares after: 7,730
Date: 23 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 975
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).

Footnote F2

Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.